Minimal clinically important difference for pain on the VAS scale and the relation to quality of life in women with endometriosis.

Objectives: The minimal important difference can be helpful in interpreting data from clinical trials. The objective of the study was to calculate the minimal important difference for improvement on the VAS scale for women with endometriosis.

Study Design: A prospective study was conducted to evaluate the effect of pertubation with lignocaine on dysmenorrhea and quality of life in women with endometriosis.

Effect of Lignocaine on IL-6, IL-8, and MCP-1 in Peritoneal Macrophages and Endometriotic Stromal Cells.

Objective: The objective was to evaluate the effect of lignocaine on cytokine expression and secretion in vitro in peritoneal fluid macrophages and endometriotic stromal cells.

Design: Experimental in vitro study on human cells.

Population And Sample: Peritoneal fluid (n = 10) and samples from endometriotic cysts (n = 7) were collected from 13 women (women with endometriosis n = 8, and healthy controls n = 5) during surgery for clinical reasons.

Quality of life in patients with endometriosis and the effect of pertubation with lidocaine - a randomized controlled trial.

Objective: Pertubation with lidocaine has been shown to reduce pain (on a VAS-scale) in women with endometriosis. A clinical study was performed to evaluate the effect of lidocaine pertubations on quality of life.

Design: Double-blind, randomized and controlled trial.

Serum concentration of lignocaine after pertubation: an observational study.

Objective: The objective of this study was to report the serum concentration of lignocaine after pertubation in patients with endometriosis.

Design: Prospective observational study.

Setting: The study was carried out at a gynaecological outpatient unit in Stockholm, Sweden.

A pilot study of facial, cranial and brain MRI morphometry in men with schizophrenia: part 2.

This pilot study applies a new 3D morphometric MR method to test the hypothesis that men with schizophrenia (vs. controls) have deviant facial shapes and landmark relations in cranio/facial/brain (CFB) regions. This constitutes Part 2 of paired articles in this issue of Psychiatry Research: Neuroimaging, in which Part 1 presents the new method in detail.